Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma

Area of Science:

• Oncology
• Hematology
• Clinical Research

Background:

• Advanced diffuse large-cell lymphoma (DLCL) requires identification of prognostic factors for effective treatment.
• Previously untreated adult patients with advanced DLCL were analyzed to determine survival predictors.

Purpose of the Study:

• To identify independent prognostic factors for survival in advanced diffuse large-cell lymphoma.
• To stratify patients into risk groups based on identified prognostic factors.

Main Methods:

• Retrospective analysis of 105 previously untreated adult DLCL patients (Stage III/IV) treated with cyclophosphamide, doxorubicin, vincristine, prednisone, and bleomycin (CHOP-Bleo).
• Statistical analysis using a proportional hazards model to identify independent risk factors.
• Tumor burden and lactic dehydrogenase (LDH) levels were assessed as prognostic indicators.

Main Results:

• Overall 5-year survival was 50%; 74 patients achieved complete remission (CR).
• Lactic dehydrogenase (LDH) level and tumor burden were identified as independent risk factors for survival, remission achievement, and relapse-free survival.
• Three distinct patient risk groups were identified with 5-year survival rates of 87%, 48%, and 20%.

Conclusions:

• Lactic dehydrogenase (LDH) level and tumor burden are crucial prognostic factors in advanced DLCL.
• These factors can guide treatment program development, regimen comparison, and prognosis assessment.
• The proposed tumor burden measure, combined with LDH, offers a valuable tool for managing DLCL patients.